Unique ID issued by UMIN | UMIN000043266 |
---|---|
Receipt number | R000049383 |
Scientific Title | A cross-sectional study on the significance of measuring amino acids in understanding the pathogenesis of non-alcoholic fatty liver disease |
Date of disclosure of the study information | 2021/02/08 |
Last modified on | 2021/02/06 19:06:18 |
A cross-sectional study on measuring amino acids in fatty liver
A study to measure amino acids in fatty liver
A cross-sectional study on the significance of measuring amino acids in understanding the pathogenesis of non-alcoholic fatty liver disease
A study to measure amino acids in non-alcoholic fatty liver disease
Japan |
non-alcoholic fatty liver disease
Hepato-biliary-pancreatic medicine |
Others
NO
To search for biomarkers of development of nonalcoholic fatty liver disease (NAFLD), we will analyze D-amino acids and L-amino acids in serum and stool of patients with NAFLD
Others
The identification of characteristic composition of D- and L-body amino acids in nonalcoholic fatty liver disease.
Comparison of serum and fecal amino acid concentrations between NAFLD and non-NAFLD patients
Observational
20 | years-old | <= |
85 | years-old | >= |
Male and Female
Patients who have been diagnosed with NAFLD by histological or imaging studies within 6 months.
Patients who have not been diagnosed with NAFLD by imaging studies such as ultrasonography and MRI within 6 months.
Patients who have used antimicrobial agents within one month of blood and stool specimen collection
Patients who have been diagnosed with infectious hepatitis (hepatitis B or C, HIV infection), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilson's disease, drug-induced hepatitis, alcoholic hepatitis, or are known to consume excessive amounts of alcohol
Patients who are unable to collect specimens due to defecation disorder.
Patients who do not wish their medical information to be used for research purposes.
Patients who are judged by the physician to be unsuitable for the study.
500
1st name | Michihiro |
Middle name | |
Last name | Iwaki |
Yokohama City University Hospital
Department of Gastroenterology and Hepatology
236-0004
3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa
0457872800
michihir@yokohama-cu.ac.jp
1st name | Michihiro |
Middle name | |
Last name | Iwaki |
Yokohama City University Hospital
Department of Gastroenterology and Hepatology
236-0004
3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa
0457872800
michihir@yokohama-cu.ac.jp
Department of Gastroenterology and Hepatology, Yokohama City University Hospital
None
Other
Drug Discovery Department, Chemistry Research Group, EA Pharma Co., Ltd
Yokohama city university, Institutional Review Board for Medical and Health Research Involving Human Subjects
3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa
0457872640
rinri@yokohama-cu.ac.jp
NO
2021 | Year | 02 | Month | 08 | Day |
Unpublished
Open public recruiting
2021 | Year | 02 | Month | 05 | Day |
2021 | Year | 02 | Month | 05 | Day |
2021 | Year | 02 | Month | 06 | Day |
2026 | Year | 01 | Month | 31 | Day |
study design:
Cross sectional study
Items to measure:
blood biochemical tests, urinalysis, tissue examination by liver biopsy, Liver stiffness and liver fat content by MRI, Amino acids in stool and blood, Intestinal bacteria analysis, Metabolite analysis in stool
2021 | Year | 02 | Month | 06 | Day |
2021 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049383
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |